Drug Supply Chain Integrity Articles & Analysis
24 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. These new services will support ...
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. With cutting-edge solutions in the field of microneedle technology, Protheragen-ING is on the front lines in this field. As a certified ISO9001 supplier of pharmaceutical ingredients and specialty chemicals, Protheragen-ING keeps ...
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
CD BioSciences, a leading customer-focused biotechnology company based in New York, introduces new GPCR purification services to support and facilitate GPCR research and drug development. CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. With more than 800 members, G protein-coupled receptors (GPCRs) constitute the largest ...
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo ...
ByIktos
Packaging is another factor that decides the stability and integrity of drugs. Except for the role as an excipient producer and supplier, the US-based CRO company CD Formulation today announces that it newly launches a wide range of pharmaceutical packaging services, providing support throughout the whole process of packaging design, from material selection to chemical and surface analysis and to ...
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer applications. Computer-aided drug design (CADD) has penetrated into all ...
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. The collaboration aims to provide patients and their oncologists with more information as to what therapies could ...
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. An interim case summary was included in SEngine’s poster presentation at the AACR 2021 annual meeting. The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
Experienced machine learning and engineering leader Andrew Watson joins Healx from technology giant Dyson as VP of Artificial Intelligence. In his new role, Andrew will deepen the investment in Healx’s artificial intelligence team and scale Healx’s technical capabilities in order to identify and progress more novel treatments for rare diseases. Andrew’s appointment reinforces ...
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...
SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual ...
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...